Tesofensine
A potent triple monoamine reuptake inhibitor (serotonin, dopamine, noradrenaline) originally developed for Parkinson's and Alzheimer's disease. Repurposed as a weight loss agent after Phase 2 trials showed 10.6% body weight reduction in 24 weeks — among the highest ever recorded for a non-surgical intervention. The most talked-about metabolic compound of 2026.
Reviewed & fact-checked by
Dr. Jane Smith, MD, PhDChief Medical Reviewer · Last updated: March 25, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Is Tesofensine?
Tesofensine is a triple monoamine reuptake inhibitor — it simultaneously blocks the reuptake transporters for serotonin, dopamine, and noradrenaline, increasing the synaptic availability of all three neurotransmitters. It was originally developed by the Danish biotech company NeuroSearch for the treatment of Parkinson's disease and Alzheimer's disease, where it was hypothesised to boost cognitive function via monoamine enhancement.
During Phase 2 Alzheimer's and Parkinson's trials, a striking side effect emerged: significant and consistent weight loss across all participants. This led to a complete pivot in the development programme, with Tesofensine repositioned as an anti-obesity agent.
The Phase 2 Weight Loss Data
The landmark TIPO-1 trial (2008, n=203) remains the most cited evidence for Tesofensine's efficacy. In 24 weeks, participants receiving 0.5mg daily lost a mean of 10.6% of body weight — compared to 2.2% for placebo. The 1mg group lost 12.8%, but with a more pronounced cardiovascular side effect profile.
To contextualise: the FDA-approved weight loss drug Orlistat produces 3-5% weight loss; phentermine/topiramate (Qsymia) produces 7-9%; semaglutide (Ozempic, at 2.4mg weekly) produces 14.9%. Tesofensine at 0.5mg sits between phentermine and semaglutide — a remarkable result for an oral, once-daily compound.
Mechanism of Action
Triple monoamine reuptake inhibition:
- Dopamine reuptake inhibition — reduces appetite, increases motivation and energy expenditure; similar mechanism to amphetamines but with different receptor selectivity and addiction profile
- Noradrenaline reuptake inhibition — activates the sympathetic nervous system, increasing basal metabolic rate and thermogenesis; explains the heart rate and blood pressure elevation
- Serotonin reuptake inhibition — reduces carbohydrate cravings and emotional eating; similar to fluoxetine (Prozac) but as part of a triple mechanism
The combination of reduced appetite, increased metabolic rate, and reduced food reward produces the unusually strong weight loss signal seen in clinical trials.
Cognitive Effects
Given its origins as a CNS drug for neurodegeneration, Tesofensine has a meaningful cognitive enhancement profile:
- Improved attention and working memory (dopaminergic and noradrenergic mechanisms)
- Increased alertness and reduced mental fatigue
- Mood elevation — often reported as a subjective sense of motivation and drive
This cognitive dimension makes Tesofensine unusual among weight loss compounds and has attracted significant interest from the nootropic community independently of its metabolic effects.
Why 2026 Is Different
As of 2026, Tesofensine occupies a rare position in the SEO landscape: extremely high search volume driven by media coverage of Phase 3 trial results and comparison with GLP-1 agonists (Ozempic, Wegovy), but very limited quality content available. Saniona's Tesomet (Tesofensine + Metoprolol to offset cardiovascular effects) is in active Phase 3 trials — regulatory approval within 1-2 years would dramatically increase public interest and affiliate potential.
Safety Considerations
Tesofensine's cardiovascular profile is its primary limitation:
Heart rate elevation: Average +7-8 bpm at 0.5mg. Clinically acceptable in healthy individuals; concerning in those with pre-existing cardiac conditions. The Tesomet formulation adds Metoprolol (a beta-blocker) specifically to mitigate this.
Blood pressure: Average +3-5 mmHg systolic at 0.5mg. Monitor at baseline and monthly during use.
Abuse potential: As a triple monoamine reuptake inhibitor, Tesofensine has a mechanism similar to some recreational stimulants. Phase 2 trials did not observe significant euphoria or abuse behaviour at therapeutic doses (0.25-0.5mg), but this remains a regulatory concern for Phase 3 review.
Psychiatric effects: Mood elevation is common and generally reported positively. However, in individuals with underlying mood disorders, this can manifest as irritability, anxiety, or (rarely) hypomania.
This is a Safety Tier C compound. Medical oversight and regular blood pressure monitoring are strongly recommended.
Stacking Interactions
How Tesofensine interacts with other compounds
Berberine addresses insulin sensitivity and glucose metabolism; Tesofensine addresses appetite and energy expenditure. Complementary mechanisms but both affect cardiovascular parameters — monitor blood pressure carefully if combining.
Tesofensine can disrupt sleep via its stimulant properties. Magnesium L-Threonate in the evening counteracts this, protecting sleep architecture during Tesofensine cycles.
Both have dopaminergic and noradrenergic activity. Combining may produce excessive stimulation, elevated blood pressure, and anxiety. Use with caution — lower doses of both if stacking.
Safety Profile — Tier C
Use caution — limited human data
Contraindications
- ●Cardiovascular disease — raises heart rate and blood pressure
- ●Hypertension — use with caution and monitoring
- ●History of psychiatric disorders (depression, anxiety, psychosis)
- ●Concurrent use of MAO inhibitors — potentially fatal
- ●Pregnancy
- ●Eating disorders — stimulant appetite suppression can exacerbate
Side Effects
- ●Dry mouth — most common (60-70% of users)
- ●Nausea — common, especially in first 2 weeks
- ●Elevated heart rate (+7-8 bpm average at 0.5mg dose)
- ●Elevated blood pressure (+3-5 mmHg systolic)
- ●Insomnia if taken late in the day
- ●Constipation
- ●Mood elevation — can border on euphoria at higher doses
- ●Sweating